---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-060785"
form_type: "8-K"
ticker: null
cik: "0001828522"
company_name: "eFFECTOR Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T12:06:31.940503+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants eFFECTOR Therapeutics additional 180 days to regain $1 bid price compliance

## Summary
- Received Nasdaq letter on Feb 28, 2023, extending compliance deadline to Aug 28, 2023.
- Previously had until Feb 27, 2023, to meet minimum $1.00 closing bid price requirement.
- Company may pursue a reverse stock split (if stockholder-approved) to regain compliance.
- If not compliant by Aug 28, 2023, Nasdaq will issue delisting notice; appeal rights exist.
- No assurance of regaining compliance or maintaining other Nasdaq listing requirements.

## SEC filing metadata
- accession: 0001193125-23-060785
- form_type: 8-K
- cik: 0001828522
- company_name: eFFECTOR Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828522/000119312523060785/0001193125-23-060785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828522/000119312523060785/d473405d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-060785
- JSON: https://secwatch.observer/filing/0001193125-23-060785.json
- Plain text: https://secwatch.observer/filing/0001193125-23-060785.txt

## Key facts
- Listing & Compliance Notices
  eFFECTOR Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: February 28, 2023, the Company received a second letter from Nasdaq advising that the Company had been granted an additional 180 calendar days, or to August 28, 2023, to regain compliance with the Minimum Bid Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement, including potentially implementing a reverse stock split of its outstanding common stock (if approved by the Company’s stockholders) to att
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312523060785/0001193125-23-060785-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.